Nutrition 21 Inc. expected to Report Q3 2010 Results on May 10, 2010. This event was calculated by Capital IQ (Created on March 2, 2010).

Nutrition 21 Inc. announced that chromium picolinate has been officially approved for sale in Canada as a natural health product by Health Canada the Canadian federal agency devoted to maintaining and improving the health of the nation's citizens. As a result of this approval, Nutrition 21 can now sell its ChromaxR brand of chromium picolinate to Canadian manufacturers, marketers, and importers of natural health products. Natural health products (referred to as dietary supplements in the U.S.) require approval from Health Canada prior to marketing in Canada. After reviewing the safety and efficacy of chromium picolinate, Health Canada issued a revised monograph which now allows applicants access to an expedited licensing process taking less than 60 days. This process can help manufacturers more quickly get chromium picolinate products into the Canadian market.

Nutrition 21 Inc. announced unaudited consolidated financial results for the second quarter and six months ended December 31, 2009. The company reported total revenues from continuing operations of $2.1 million for the second quarter compared to $1.6 million in the corresponding quarter a year ago. Net loss from continuing operations was $0.6 million or $0.01 per diluted common share compared to net loss of $1.4 million or $0.02 per diluted common share, in the corresponding second quarter a year ago. Operating income was $0.3 million against loss of $0.3 million last year. For the six months, the company reported total revenues from continuing operations of $4.4 million compared to $3.5 million in the comparable period a year ago. Net loss from continuing operations was $1.1 million or $0.02 per diluted common share compared to $2.4 million or $0.4 per diluted common share in the corresponding period a year ago. The improvement in continuing operations is due primarily to the company's continuing emphasis on expense control and strong chromium picolinate sales, primarily for human consumption. Operating income was $0.8 million against loss of $0.2 million last year.